The clinical outcomes of undifferentiated pleomorphic sarcoma (UPS): A single-centre experience of two decades with the assessment of PD-L1 expressions.

  title={The clinical outcomes of undifferentiated pleomorphic sarcoma (UPS): A single-centre experience of two decades with the assessment of PD-L1 expressions.},
  author={Kyoungmin Lee and Joon Seon Song and Jeong Eun Kim and Wanlim Kim and Si Yeol Song and Min Hee Lee and Hye Won Chung and Kyung-Ja Cho and Jong-Seok Lee and Jin-Hee Ahn},
  journal={European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology},
  • Kyoungmin Lee, J. Song, Jin-Hee Ahn
  • Published 24 February 2020
  • Medicine
  • European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
Undifferentiated pleomorphic sarcoma of the extremity and trunk: a retrospective cohort study of 166 cases in a large institution
The existing study reveals that the UPS in trunk, tumor size ≥5 cm and R1/R2 resection margin are the prognostic markers of poor survival rate, which was correlated with LRFS, DMFS, and OS.
Undifferentiated Pleomorphic Sarcoma of the Extremity and Trunk: A Retrospective Cohort Study of 166 Cases in a Large Institution
R0 resection margin was an only independent favorable prognostic factor, which was correlated with LRFS, DMFS, and OS, and reveals that the UPS in trunk and R1/R2 resectionmargin are the prognostic markers of poor survival rate.
Undifferentiated Pleomorphic Sarcoma with Neoplastic Fever: A Retrospective Study
This study retrospectively analyzed the clinical data of patients with UPS to provide a reference for the diagnosis and treatment of UPS with neoplastic fever, which is characterized by intratumoral necrosis and extensive edema of the surrounding soft tissues.
Novel Nomograms-Based Prediction Models for Patients with Primary Undifferentiated Pleomorphic Sarcomas Resections
Two nomograms are developed that are able to predict 3- and 5-year overall survival (OS) and time to recurrence (TTR) for UPS patients for the first time and show relatively good accuracy and practicability.
Serum lactate dehydrogenase as a novel prognostic factor for patients with primary undifferentiated pleomorphic sarcomas
Preoperative serum LDH is an independent factor for OS in UPS patients, and it correlates with future surgical margin, and Kaplan–Meier curves showed that patients with relatively high-serum LDH had poorer OS compared with those with low-seru LDH.
The potentiality of immunotherapy for sarcomas: a summary of potential predictive biomarkers.
Potential biomarkers of immunotherapy for treatment of sarcomas focused on PD-1/PD-L1 inhibitors, which play a crucial role in the progression of tumor by altering status of immune surveillance.
Giant pleomorphic sarcoma of the tongue base – a cured clinical case report and literature review
This case presented surprisingly a favorable evolution despite the huge dimensions, the tumor type, and associated pathology, and the evolution was without relapse after 18 months.
Facts and Hopes in Immunotherapy of Soft-Tissue Sarcomas
The facts and the hopes for the patients with sarcoma are presented, as the field is rapidly advancing its understanding of what and where to use the various types of immunotherapies.
Undifferentiated Pleomorphic Sarcoma


Clinicopathologic re-evaluation of 100 malignant fibrous histiocytomas: prognostic relevance of subclassification.
Reclassified 100 tumors of the extremity and trunk wall primarily diagnosed as MFH confirmed that most so-called MFH can be subclassified by defined criteria; it provides evidence that such classification is clinically important.
Treatment results and prognostic factors in patients with malignant fibrous histiocytoma
Staging system is a prognostic predictor for overall survival rates and postoperative radiotherapy can improve local control, however, the optimal adjuvant treatment strategy for MFH should still be further explored.
Malignant Fibrous Histiocytoma: A Retrospective Study of 109 Cases
Complete surgical resection at the time of primary tumor presentation is likely to afford the best chance for RFS and OS, and radiation therapy plays an important role, in combination with surgery for better local control, particularly in high-grade lesions, and in cases with positive surgical margins after wide complete gross excision.
Clinicopathological and prognostic significance of PD-L1 expression in sarcoma
The findings from this meta-analysis indicate that PD-L1 expression might be a useful predicative factor of poor prognosis for patients with bone and soft tissue sarcoma.
Histologic and Genetic Advances in Refining the Diagnosis of “Undifferentiated Pleomorphic Sarcoma”
Undifferentiated pleomorphic sarcoma (UPS) is an inclusive term used for sarcomas that defy formal sub-classification and when implemented, careful histologic assessment, immunohistochemistry, and ultra-structural evaluation can often determine lineage of differentiation.
Most Malignant Fibrous Histiocytomas Developed in the Retroperitoneum Are Dedifferentiated Liposarcomas: A Review of 25 Cases Initially Diagnosed as Malignant Fibrous Histiocytoma
It is shown that most so-called malignant fibrous histiocytomas developed in the retroperitoneum are dedifferentiated liposarcoma and that a poorly differentiated sarcoma in this area should prompt extensive sampling to demonstrate a well-differentiated lipo-based component, immunohistochemistry for mdm2 and cdk4, and if possible, a cytogenetic or a molecular biology analysis.
Status of programmed death-ligand 1 expression in sarcomas
It is demonstrated that PD-L1 protein is highly expressed in pleomorphic rhabdomyosarcoma, fibrosarcomA, and dedifferentiated liposarComa (DDLPS) cell lines, and this results may serve as primary data for the selection of appropriate patients when applying PD1/PD-L 1 inhibitor therapy in sarcoma.
Patterns of Chemotherapy Administration in High-Risk Soft Tissue Sarcoma and Impact on Overall Survival.
BACKGROUND Conflicting data exist on the benefit of chemotherapy in the management of high-risk soft tissue sarcoma (STS). Use of chemotherapy may be dependent on patient, tumor, and facility
Evidence-based recommendations for local therapy for soft tissue sarcomas.
For patients with higher risk disease (stage III), the available randomized trials do not convincingly demonstrate a clinical benefit to adjuvant chemotherapy, and a complete accounting of potential risks and benefits is appropriate when discussing adjUvant chemotherapy with patients who have stage III disease.